Category: Press Releases

Cyclarity

Cyclarity Unveils Oxidized Cholesterol Excretion Data

Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease,

BioAge Labs

BioAge Reports Positive Phase 1 Data for BGE-102

BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today reported results

2026 HLIS

APLMS and Kitalys to Host Healthy Longevity in Hong Kong

The Asia-Pacific Longevity Medicine Society (APLMS), in partnership with The Kitalys Institute, announced that the 2026 Asia-Pacific Healthy Longevity International Summit (APAC-LMIS) will be held in Hong Kong from October

Rubedo

Rubedo Announces Positive Preliminary Results for RLS-1496

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized,

BioAge Labs

BioAge Labs Provides Business Updates

BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided financial results for the

Healthspan Horizons

Buck Institute Launches Healthspan Horizons

The Buck Institute for Research on Aging today announced the launch of Healthspan Horizons, a new initiative designed to address one of the most urgent challenges in modern medicine: how to

Vitalist Bay

Vitalist Bay 2026 Returns to Berkeley May 14–17

BERKELEY, CA — The Vitalism Foundation announces Vitalist Bay 2026, the world’s largest longevity festival, returning to the Lighthaven Campus in Berkeley, California from May 14–17, 2026. Now in its

Longevity Innovation Forum 2026

Longevity Innovation Forum in San Diego

San Diego, CA – March 11–12, 2026 – Longevity Global will host the inaugural Longevity Innovation Forum, a two-day gathering bringing together leading scientists, clinicians, biotech founders, investors, and longevity

China Launches Standardized Physician Education in Longevity

Beijing, China — In response to the growing healthcare demands of a rapidly ageing population, China has launched its first national competency-based education programme in longevity medicine, marking a significant step toward integrating healthy longevity and preventive care into mainstream clinical practice. The initiative was jointly

Cyclarity

Cyclarity Unveils Oxidized Cholesterol Excretion Data

Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease, has just unveiled data from a clinical trial of its lead candidate, UDP-003, at the American Heart

AI for Practical Longevity

Forever Healthy Releases AI4L 1.0 for Practical Longevity

We are super excited to share with you that today we released AI4L – “AI for Practical Longevity”, an open-source system that enables anyone to produce rigorous, evidence-based reviews of health and longevity interventions using frontier AI models. Our novel “Audit-Driven Prompting” method enables iterative self-auditing

Non-Fungible Conference

Longevity Day at NFC Summit Lisbon Announces Speaker Lineup

Longevity Day at NFC Summit Lisbon has announced its confirmed speaker lineup ahead of its debut on 4 June 2026 at the Unicorn Factory in Lisbon. The event will bring together scientists, clinicians, founders, and investors from across the longevity ecosystem for a full-day program spanning

BioAge Labs

BioAge Reports Positive Phase 1 Data for BGE-102

BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today reported results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small

2026 HLIS

APLMS and Kitalys to Host Healthy Longevity in Hong Kong

The Asia-Pacific Longevity Medicine Society (APLMS), in partnership with The Kitalys Institute, announced that the 2026 Asia-Pacific Healthy Longevity International Summit (APAC-LMIS) will be held in Hong Kong from October 1–4, 2026, at the Hopewell Hotel. The Summit is expected to bring together more than 2,000

Rubedo

Rubedo Announces Positive Preliminary Results for RLS-1496

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The

BioAge Labs

BioAge Labs Provides Business Updates

BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2025 and business updates for the fourth quarter ended December 31,

Healthspan Horizons

Buck Institute Launches Healthspan Horizons

The Buck Institute for Research on Aging today announced the launch of Healthspan Horizons, a new initiative designed to address one of the most urgent challenges in modern medicine: how to measure, understand, and extend healthspan—the years of life spent in good health. People are living longer—but

NOVA 2026

Neuroscience of Vitality and Aging Conference in Boston

For the first time, the Neuroscience of Vitality and Aging (NOVA) Conference is bringing together leaders from across neuroscience, biotechnology, policy, and investment to examine one of the most urgent questions in medicine today: how to preserve brain health across the lifespan and accelerate progress against

LongX Logo

Xplore Program 2026: A Remote Summer Fellowship in Longevity

For the third summer in a row, Longevity Xplorer (LongX) is opening applications for the Xplore Program, a fully remote summer fellowship designed to help students and early-career professionals translate interest in longevity into practical experience. The program is structured to do two things well: (1)

Vitalist Bay

Vitalist Bay 2026 Returns to Berkeley May 14–17

BERKELEY, CA — The Vitalism Foundation announces Vitalist Bay 2026, the world’s largest longevity festival, returning to the Lighthaven Campus in Berkeley, California from May 14–17, 2026. Now in its second year, Vitalist Bay condenses the scope into four high-intensity days and six themes — Biotech,

NUS Healthy Longevity Conference

Global Conference to Tackle Longevity Clinical Translation

The NUS Academy for Healthy Longevity invites you to the Geromedicine Conference, set to take place from February 26-27, 2026, at the National University of Singapore. This premier event will gather global experts in geroscience, researchers, clinicians and industry leaders to explore the translation of geroscience

Longevity Innovation Forum 2026

Longevity Innovation Forum in San Diego

San Diego, CA – March 11–12, 2026 – Longevity Global will host the inaugural Longevity Innovation Forum, a two-day gathering bringing together leading scientists, clinicians, biotech founders, investors, and longevity enthusiasts advancing the science and translation of healthy aging. Held in San Diego’s thriving biotech hub,

Life Biosciences

Life Biosciences Announces FDA Clearance of IND for ER-100

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ER-100. The IND clearance allows Life Bio